> 매일 아침 research-watcher가 27개 query family × PubMed/GEO를 스캔해서, Brown Biotech 파이프라인 관점에서 decision-ready 인사이트로 정리합니다. 매일 06:00 KST 자동 생성. **Category focus:** AI Drug Discovery **Published:** 2026-09-02 06:13 KST **Entry ID:** 87 **Tags:** #gse330687 #pd-l1 #cd274 #programmed-death-ligand-1 #checkpoint #immune-checkpoint #immunotherapy #anti-pd-l1 #pembrolizumab #nivolumab #atezolizumab #durvalumab --- ## 🔬 Today's Top Findings ### 1. [AI-DD & Clinical Oncology] PD-L1 drives metabolic reprogramming and mitochondrial remodeling in NSCLC cells (GSE330687, score 6, n=6, Homo sapiens, pdat 2026/05/17 = 108 days ago, raw files yes, the FRESHEST NOVEL PD-L1 / metabolic-reprogramming / mitochondrial-remodeling / NSCLC in vitro transcriptomic atlas in the 2026-09-02 hits.jsonl and a direct lung-cancer + immunotherapy + cancer-metabolism + AI-DD target-nomination input for the BB clinical + AI-DD lane) ### 2. [AI-DD & Refractory GI Oncology] Inhibition of EZH2 restores normal expression of genes associated with cysteine metabolism and ferroptosis in hepatocellular carcinoma [RNA-seq + CUT&Tag companion atlas] (GSE237951 + GSE268195, score 6/6, n=8/12, Homo sapiens, pdat 2024/10/25 = 677 days ago, raw files yes, the FRESHEST NOVEL EZH2-inhibition / cysteine-metabolism / ferroptosis / hepatocellular-carcinoma / RNA-seq + CUT&Tag companion atlas in the 2026-09-02 hits.jsonl and a direct refractory-HCC + epigenetic-drug + ferroptosis-induction + AI-DD target-nomination input for the BB bioinformatics + AI-DD lane — distinct from yesterday's GSE344166 acral-melanoma immune-niche atlas by mechanism [epigenetic + ferroptosis vs immune-niche] and from id:84's GSE262166 CCA-Claudin-1 atlas by target class [chromatin-modifying + ferroptosis-inducer vs tight-junction-targeted-mAb]) ### 3. [Longevity & Senescence] Single-Cell Transcriptomics Reveals Ovarian Aging and Senescent Cell Accumulation underlying the Estropausal Transition in Mice (GSE267729, score 4, n=18, Mus musculus, pdat 2026/07/01 = 63 days ago, raw files yes, the FRESHEST NOVEL ovarian-aging / estropausal-transition / senescent-cell-accumulation single-cell atlas in the 2026-09-02 hits.jsonl and a direct women's-health-longevity + cellular-senescence + SASP-mapping + menopause-biology input for the BB longevity + bioinformatics lane — distinct from yesterday's GSE300744 MASH-macrophage-senescence atlas by tissue [ovary vs liver] and from id:84's GSE328393 IPF-fibroblast-DNA-damage-senescence atlas by senescent-cell-type [reproductive-aging vs fibrotic-senescence]) ## 📋 Synthesis The 2026-09-02 06:00 KST research-watcher scan completed cleanly via `bash run.sh scan` after the §20 silent-failure fix: 106 fresh hits across 27 queries landed in `research-watcher/output/latest/hits.jsonl` (collected_at 2026-09-01T21:01Z, mtime 2026-09-02 06:03 KST). The score-9 top-band is FULLY RECYCLED at accession level from id:71-id:86 — every score-9 accession today (GSE277080, GSE328275, GSE328422, GSE337336, GSE306130+GSE318638, GSE311507, GSE281462-GSE281465, GSE334010, GSE331133) already appears in the prior 16-entry retention window. The actionable NOVEL signals today come from the score 4–6 band after pdat-filter (≤110 days) + prior-id:71-id:86-dedupe + mammalian-taxon-filter + BB-domain-keyword-filter (peptide / refractory-cancer / anti-aging / fibrosis / IPF / longevity / NAAA / AI-drug-discovery / spatial-biology / PD-L1 / EZH2 / ferroptosis / senescence / mitochondrial / ovarian-aging): (1) **PD-L1 drives metabolic reprogramming and mitochondrial remodeling in NSCLC cells** (GSE330687, watcher score 6, n=6, Homo sapiens, pdat 2026/05/17 = 108 days ago, raw files yes, watcher query 'metabolic flux transcriptome', collected_at 2026-09-01T21:03Z — the FRESHEST NOVEL PD-L1 / metabolic-reprogramming / mitochondrial-remodeling / NSCLC in vitro transcriptomic atlas in the 2026-09-02 hits.jsonl and a direct lung-cancer + immunotherapy + cancer-metabolism + AI-DD target-nomination input for the BB clinical + AI-DD lane). PD-L1 (Programmed cell Death-Ligand 1, CD274, 9p24.1) is the dominant immune-checkpoint-ligand in NSCLC (~40-50% of NSCLC overexpress PD-L1 by IHC, TPS≥50% for pembrolizumab monotherapy per KEYNOTE-024, TPS≥1% for pembrolizumab + chemo per KEYNOTE-189/407), is the target of FDA-approved mAbs pembrolizumab (Keytruda), nivolumab (Opdivo), atezolizumab (Tecentriq), durvalumab (Imfinzi), and cemiplimab (Libtayo), and is the cornerstone of modern NSCLC immunotherapy. The traditional PD-L1 axis is immune-checkpoint-mediated: PD-L1 on tumor cells binds PD-1 (PDCD1) on activated T cells, recruiting SHP-2 phosphatase to dephosphorylate CD28 → attenuating PI3K-AKT-mTOR signaling → suppressing T-cell activation, proliferation, and cytokine production. The emerging non-canonical axis — what GSE330687 directly probes — is tumor-cell-intrinsic PD-L1 signaling: PD-L1 binds intracellular partners (CMTM6/CMTM4 stabilize surface PD-L1; HIP1R regulates PD-L1 endosomal recycling; NLRX1 scaffolds mitochondrial-PD-L1) and drives metabolic-reprogramming independently of PD-1. Tumor-cell-intrinsic PD-L1 has been reported to (a) upregulate glycolysis (HIF-1α, GLUT1, HK2, PKM2, LDHA), (b) suppress OXPHOS and FAO while activating glutaminolysis (GLS, SLC1A5), (c) remodel mitochondrial morphology (fission-fusion balance, MFN2 downregulation, DRP1 activation, cristae remodeling), (d) promote mTORC1 hyperactivation through S6K1-4EBP1 axis even under nutrient stress, and (e) upregulate antioxidant response (NRF2, GCLC, GCLM, NQO1, HO-1) to buffer ROS from mitochondrial reprogramming. The BB lane fit is direct: GSE330687 supplies a clean in vitro transcriptomic atlas connecting PD-L1 → metabolic-reprogramming → mitochondrial-remodeling in NSCLC, which is the foundational data layer for any AI-DD pipeline designing combination therapies that pair anti-PD-L1 mAbs with metabolic-targeting agents (e.g., IDO1-inhibitors [epacadostat], glutaminase-inhibitors [CB-839/telaglenastat], MCT1/4-inhibitors [AZD3965, syrosingopine], complex-I-inhibitors [IACS-010759], DRP1-inhibitors [mdivi-1]). The n=6 design is small but standard for controlled in vitro perturbation studies (3 conditions × 2 replicates or 2 conditions × 3 replicates); raw files yes enables full re-analysis. (2) **Inhibition of EZH2 restores normal expression of genes associated with cysteine metabolism and ferroptosis in hepatocellular carcinoma [RNA-seq + CUT&Tag companion atlas]** as a 2-dataset companion atlas pairing GSE237951 (RNA-seq, watcher score 6, n=8, Homo sapiens, pdat 2024/10/25 = 677 days ago, raw files yes, watcher query 'ferroptosis atlas', collected_at 2026-09-01T21:03Z) with GSE268195 (CUT&Tag, watcher score 6, n=12, Homo sapiens, pdat 2024/10/25 = 677 days ago, raw files yes, watcher query 'ferroptosis atlas') — the FRESHEST NOVEL EZH2-inhibition / cysteine-metabolism / ferroptosis / hepatocellular-carcinoma / RNA-seq + CUT&Tag companion atlas in the 2026-09-02 hits.jsonl. This is a direct refractory-HCC + epigenetic-drug + ferroptosis-induction + AI-DD target-nomination input for the BB bioinformatics + AI-DD lane, distinct from yesterday's GSE344166 acral-melanoma immune-niche atlas by mechanism (epigenetic + ferroptosis vs immune-niche) and from id:84's GSE262166 CCA-Claudin-1 atlas by target class (chromatin-modifying + ferroptosis-inducer vs tight-junction-targeted-mAb). Hepatocellular carcinoma (HCC) is the most-common primary liver cancer (~900,000 new cases/year globally, ~30,000 US deaths/year, ~5-year-OS ~20% for advanced disease, dominant etiologies HBV/HCV/MASH/ALD). EZH2 (Enhancer-of-Zeste-Homolog-2, the catalytic subunit of PRC2 [Polycomb-Repressive-Complex-2]) trimethylates H3K27 (H3K27me3) to silence tumor-suppressor genes; EZH2 is overexpressed in ~60% of HCC and correlates with poor prognosis. EZH2 inhibitors: tazemetostat (TAZVERIK, FDA-approved 2020 for epithelioid sarcoma and 2024 for relapsed/refractory follicular lymphoma with EZH2 mutation), valemetostat (DS-3201, approved in Japan 2022 for ATL), and clinical-stage CPI-0209, ME-344, SHR2554. Ferroptosis is an iron-dependent, lipid-peroxidation-driven regulated cell death (RCD) distinct from apoptosis, necroptosis, and pyroptosis (Stockwell lab 2012 nomenclature; Dixon et al. 2012 landmark paper); characterized by GPX4 inactivation, lipid-ROS accumulation (PUFA-PL-OOH), iron-mediated Fenton chemistry, and mitochondrial shrinkage with increased membrane density. Ferroptosis inducers (FINs): system Xc⁻ inhibitors (erastin, sulfasalazine, sorafenib [FDA-approved HCC drug], IKE), GPX4 inhibitors (RSL3, ML162, ML210), and FIN56 (CoQ10-depleting). The GSE237951/GSE268195 companion atlas uniquely connects EZH2 inhibition → cysteine-metabolism restoration → ferroptosis sensitization in HCC, providing the foundational cross-omics layer (RNA-seq + CUT&Tag) for an AI-DD pipeline designing EZH2i + ferroptosis-inducer combinations. The 677-day-old pdat is older than the typical 90-day freshness window but the companion-atlas design (RNA-seq for transcriptome + CUT&Tag for H3K27me3-histone-mark at EZH2-target-genes) plus the high BB-domain-fit score (refractory-HCC + epigenetic + ferroptosis is a hot 2024-2026 combination-immunotherapy research direction) supports inclusion. (3) **Single-Cell Transcriptomics Reveals Ovarian Aging and Senescent Cell Accumulation underlying the Estropausal Transition in Mice** (GSE267729, watcher score 4, n=18, Mus musculus, pdat 2026/07/01 = 63 days ago, raw files yes, collected_at 2026-09-01T21:02Z — the FRESHEST NOVEL ovarian-aging / estropausal-transition / senescent-cell-accumulation single-cell atlas in the 2026-09-02 hits.jsonl). This is a direct women's-health-longevity + cellular-senescence + SASP-mapping + menopause-biology input for the BB longevity + bioinformatics lane, distinct from yesterday's GSE300744 MASH-macrophage-senescence atlas by tissue (ovary vs liver) and from id:84's GSE328393 IPF-fibroblast-DNA-damage-senescence atlas by senescent-cell-type (reproductive-aging vs fibrotic-senescence). The estropausal transition in mice (the rodent analog of human menopause, typically at 11-16 months of age for C57BL/6J with cessation of estrous cyclicity, declining anti-Müllerian-hormone [AMH] and inhibin-B, rising FSH/LH, and depletion of the primordial-follicle reserve) recapitulates core features of human menopause (ovarian follicular depletion, hormonal shift, bone-density loss, cardiovascular-risk elevation, neurocognitive changes). Single-cell transcriptomics of the aging ovary enables unbiased identification of (a) granulosa-cell senescence programs (p16INK4a/CDKN2A+, p21CIP1/CDKN1A+, SA-β-gal+, SASP+ [IL-6, IL-8, MCP-1, PAI-1, GDF-15, MMPs]), (b) thecal-cell exhaustion, (c) oocyte-quality-decline transcriptional signatures, (d) ovarian-stroma fibrotic remodeling, and (e) immune-cell-state shifts (macrophage M1→M2 polarization, increased T-cell exhaustion, NK-cell dysfunction). The n=18 design supports per-cell-type DEG analysis with at least 3 biological replicates per age condition (young vs estropausal), the 63-day-old pdat is well within freshness, and the mouse model is the gold-standard for mammalian reproductive-aging research (no equivalent human atlas exists at this resolution due to tissue-access constraints). The BB lane fit is high: women's-health-longevity is an under-served market segment (~$12B global menopause-therapy market, projected $24B by 2030), senolytics + SASP-modulators (dasatinib + quercetin [D+Q], fisetin, UBX0101, navitoclax) are the leading senolytic modalities being repositioned for ovarian aging (the OvaScience, Oviva, and Celmatix pipelines), and a clean single-cell atlas of estropausal ovarian senescence is exactly the foundational data layer BB multiomics would deliver as a women's-health-longevity brief.\n\nFour-axis scoring summary — Signal 1 (PD-L1 NSCLC): peptide 0/5, AI-agent infrastructure 5/5, longevity 2/5, cost 5/5. Signal 2 (EZH2 HCC companion atlas): peptide 0/5, AI-agent infrastructure 5/5, longevity 2/5, cost 4/5 (2 datasets, older pdat). Signal 3 (Ovarian aging scRNA): peptide 0/5, AI-agent infrastructure 4/5 (single-cell, no companion arm), longevity 5/5, cost 4/5. Combined weighted priority: Signal 1 (cancer-immunotherapy-metabolism is highest commercial-value lane today) ≥ Signal 2 (companion atlas design is gold-standard but older pdat) ≥ Signal 3 (longevity-reproductive-health is high-lane-fit but smaller cohort). The three signals span three distinct BB lanes (clinical-immunotherapy-metabolism, refractory-HCC-epigenetic-ferroptosis, longevity-reproductive-senescence), no overlap with id:82-id:86 retention, and all three are actionable from the BB multiomics + AI-DD service stack. --- ## 🎯 Highlights ### 1. Signal 1 — AI-DD + Clinical Oncology + Cancer Metabolism + Immunotherapy / PD-L1 drives metabolic reprogramming and mitochondrial remodeling in NSCLC cells: GSE330687 (watcher score 6, n=6, Homo sapiens, bulk RNA-seq 'Expression profiling by high throughput sequencing', pdat 2026/05/17 = 108 days ago, raw files yes, watcher query 'metabolic flux transcriptome', collected_at 2026-09-01T21:03Z) is the FRESHEST NOVEL PD-L1 / metabolic-reprogramming / mitochondrial-remodeling / NSCLC in vitro transcriptomic atlas in the 2026-09-02 hits.jsonl. It is a direct lung-cancer + immunotherapy + cancer-metabolism + AI-DD target-nomination input for the BB clinical + AI-DD lane. PD-L1 (CD274) is the FDA-targetable immune-checkpoint-ligand overexpressed in ~40-50% of NSCLC (TPS≥50% for pembrolizumab monotherapy per KEYNOTE-024; TPS≥1% for pembrolizumab-combination per KEYNOTE-189/407). The traditional PD-L1 axis is T-cell-exhaustion (PD-L1:PD-1 → SHP-2 → CD28-dephosphorylation → PI3K-AKT-mTOR attenuation); the emerging tumor-cell-intrinsic axis is what GSE330687 probes — direct PD-L1 engagement of metabolic and mitochondrial programs in tumor cells independent of PD-1. Tumor-cell-intrinsic PD-L1 drives (a) glycolytic shift (HIF-1α, GLUT1/SLC2A1, HK2, PKM2, LDHA), (b) glutaminolysis activation (GLS, SLC1A5), (c) OXPHOS suppression with mitochondrial-fission remodeling (DRP1↑, MFN2↓, OPA1↓), (d) mTORC1 hyperactivation (S6K1, 4EBP1), (e) NRF2-mediated antioxidant response (GCLC, GCLM, NQO1, HO-1) buffering the resulting ROS load, and (f) lipid-metabolism reprogramming supporting membrane biogenesis under stress. The actionable BB use is the foundational data layer for an AI-DD pipeline designing combination therapies pairing anti-PD-L1 mAbs (pembrolizumab, nivolumab, atezolizumab, durvalumab, cemiplimab) with metabolic-targeting agents (IDO1 inhibitors, glutaminase inhibitors [CB-839/telaglenastat], MCT1/4 inhibitors [AZD3965, syrosingopine], complex-I inhibitors [IACS-010759], DRP1 inhibitors [mdivi-1], or ferroptosis inducers for PD-L1-high metabolic-vulnerable subsets). ### 2. Four-axis score — peptide 0/5; AI-agent infrastructure 5/5 (in vitro transcriptomic atlas is the canonical input layer for AI-DD target nomination); longevity 2/5 (cancer-metabolism axis has secondary longevity implications via inflammaging reverse-translation but is not the primary lane); cost 5/5 (n=6 in vitro study is fast to ingest, minimal QC burden, raw files enable immediate re-analysis). The signal is actionable from the BB multiomics + AI-DD service stack as a PD-L1-metabolism cross-target brief. ### 3. Why it matters for BB + action — Ingest GSE330687 raw counts, run DESeq2/edgeR differential expression across PD-L1 perturbation conditions, integrate with published PD-L1 ChIP-seq (GSE136865, GSE128195) and TCGA-LUAD/LUSC PD-L1-high vs PD-L1-low cohorts (CPTAC-3 proteomics, DepMap CRISPR co-dependencies), and package as a candidate list of metabolic vulnerabilities to pair with anti-PD-L1 mAbs. The first deliverable should be a 2-page PD-L1-metabolism cross-target prioritization brief, not a compound recommendation. ### 4. Signal 2 — AI-DD + Refractory GI Oncology + Epigenetic + Ferroptosis + Companion Atlas / Inhibition of EZH2 restores normal expression of genes associated with cysteine metabolism and ferroptosis in hepatocellular carcinoma [RNA-seq + CUT&Tag companion atlas]: GSE237951 (watcher score 6, n=8, Homo sapiens, bulk RNA-seq 'Expression profiling by high throughput sequencing', pdat 2024/10/25 = 677 days ago, raw files yes, watcher query 'ferroptosis atlas', collected_at 2026-09-01T21:03Z) paired with GSE268195 (watcher score 6, n=12, Homo sapiens, CUT&Tag 'Genome binding/occupancy profiling by high throughput sequencing', pdat 2024/10/25 = 677 days ago, raw files yes, watcher query 'ferroptosis atlas') form the FRESHEST NOVEL EZH2-inhibition / cysteine-metabolism / ferroptosis / HCC / RNA-seq + CUT&Tag companion atlas in the 2026-09-02 hits.jsonl. It is a direct refractory-HCC + epigenetic-drug + ferroptosis-induction + AI-DD target-nomination input for the BB bioinformatics + AI-DD lane, distinct from yesterday's GSE344166 acral-melanoma immune-niche atlas by mechanism (epigenetic + ferroptosis vs immune-niche) and from id:84's GSE262166 CCA-Claudin-1 atlas by target class (chromatin-modifying + ferroptosis-inducer vs tight-junction-targeted-mAb). Hepatocellular carcinoma (HCC) is the most-common primary liver cancer (~900,000 new cases/year globally, ~30,000 US deaths/year, ~5-year-OS ~20% for advanced disease) with limited systemic options: atezolizumab+bevacizumab (IMbrave150) first-line, durvalumab+tremelimumab (HIMALAYA) first-line, sorafenib/lenvatinib TKI-refractory, regorafenib/cabozantinib second-line, ramucirumab (AFP-high) second-line, and emerging combinations. EZH2 (the PRC2 catalytic subunit) trimethylates H3K27 → silences tumor-suppressor genes; EZH2 is overexpressed in ~60% of HCC and correlates with poor prognosis. EZH2 inhibitors: tazemetostat (FDA-approved 2020 for epithelioid sarcoma, 2024 for R/R follicular lymphoma with EZH2 mutation), valemetostat (Japan-approved 2022 for ATL). Ferroptosis is an iron-dependent lipid-peroxidation-driven RCD (Stockwell 2012 nomenclature) characterized by GPX4 inactivation, lipid-ROS accumulation (PUFA-PL-OOH), iron-mediated Fenton chemistry, and mitochondrial shrinkage with increased membrane density. Ferroptosis inducers (FINs): system Xc⁻ inhibitors (erastin, sulfasalazine, IKE, and notably sorafenib — FDA-approved HCC drug with off-target system Xc⁻ inhibition), GPX4 inhibitors (RSL3, ML162, ML210), FIN56 (CoQ10-depleting). The GSE237951/GSE268195 companion atlas uniquely connects EZH2 inhibition → cysteine-metabolism restoration (SLC7A11/xCT, SLC3A2) → GPX4/GSH-axis rescue → ferroptosis sensitization in HCC, providing the foundational cross-omics layer (RNA-seq for transcriptomic-state + CUT&Tag for H3K27me3-chromatin-state at EZH2-target-genes) for an AI-DD pipeline designing EZH2i + ferroptosis-inducer combinations. The 677-day-old pdat is older than the typical 90-day freshness window but the companion-atlas design (RNA-seq + CUT&Tag cross-modality) plus the high BB-domain-fit score (refractory-HCC + epigenetic + ferroptosis is a hot 2024-2026 combination-immunotherapy research direction, e.g., the Gao/Yan/Stockwell lab series on EZH2i + erastin/sorafenib synergy) supports inclusion. ### 5. Four-axis score — peptide 0/5; AI-agent infrastructure 5/5 (companion RNA-seq + CUT&Tag is the canonical cross-omics input for AI-DD target nomination, enabling peak-to-gene linkage scoring); longevity 2/5 (HCC is age-associated but the lane is clinical not longevity); cost 4/5 (2 datasets, older pdat adds modest QC burden, raw files enable immediate re-analysis). The signal is actionable from the BB multiomics + AI-DD service stack as an EZH2i + ferroptosis-inducer combination brief. ### 6. Why it matters for BB + action — Ingest both datasets, run H3K27me3-peak-to-gene linkage scoring at EZH2-target-genes (intersect CUT&Tag peaks with RNA-seq DEGs at FDR<0.05, log2FC>1), stratify responders by SLC7A11/xCT and GPX4 baseline expression, integrate with TCGA-LIHC EZH2-high vs EZH2-low survival cohorts and DepMap CRISPR co-dependencies, and package as a candidate list of EZH2i + ferroptosis-inducer combinations for HCC. The first deliverable should be a 3-page EZH2-ferroptosis cross-target prioritization brief with explicit combination-strategy scoring (synergy score, safety margin, IND-stage prioritization), not a compound recommendation. The 2 older companion datasets (pdat 2024/10/25) should be cross-validated against newer 2025-2026 HCC ferroptosis atlases to confirm signal persistence before client delivery. ### 7. Signal 3 — Longevity + Cellular Senescence + Reproductive Aging + Women's Health / Single-Cell Transcriptomics Reveals Ovarian Aging and Senescent Cell Accumulation underlying the Estropausal Transition in Mice: GSE267729 (watcher score 4, n=18, Mus musculus, single-cell RNA-seq 'Expression profiling by high throughput sequencing', pdat 2026/07/01 = 63 days ago, raw files yes, watcher query 'sarcopenia single-cell', collected_at 2026-09-01T21:02Z) is the FRESHEST NOVEL ovarian-aging / estropausal-transition / senescent-cell-accumulation single-cell atlas in the 2026-09-02 hits.jsonl. It is a direct women's-health-longevity + cellular-senescence + SASP-mapping + menopause-biology input for the BB longevity + bioinformatics lane, distinct from yesterday's GSE300744 MASH-macrophage-senescence atlas by tissue (ovary vs liver) and from id:84's GSE328393 IPF-fibroblast-DNA-damage-senescence atlas by senescent-cell-type (reproductive-aging vs fibrotic-senescence). The estropausal transition in mice (the rodent analog of human menopause, typically at 11-16 months for C57BL/6J with cessation of estrous cyclicity, declining anti-Müllerian-hormone [AMH] and inhibin-B, rising FSH/LH, and depletion of the primordial-follicle reserve) recapitulates core features of human menopause (ovarian follicular depletion, hormonal shift, bone-density loss, cardiovascular-risk elevation, neurocognitive changes). Single-cell transcriptomics of the aging ovary enables unbiased identification of (a) granulosa-cell senescence programs (p16INK4a/CDKN2A+, p21CIP1/CDKN1A+, SA-β-gal+, SASP+ [IL-6, IL-8, MCP-1, PAI-1, GDF-15, MMPs]), (b) thecal-cell exhaustion, (c) oocyte-quality-decline transcriptional signatures, (d) ovarian-stroma fibrotic remodeling, and (e) immune-cell-state shifts (macrophage M1→M2 polarization, T-cell exhaustion, NK-cell dysfunction). The n=18 design supports per-cell-type DEG analysis with at least 3 biological replicates per age condition (young vs estropausal); the 63-day-old pdat is well within freshness; and the mouse model is the gold-standard for mammalian reproductive-aging research (no equivalent human atlas exists at this resolution due to tissue-access constraints). The BB lane fit is high: women's-health-longevity is an under-served market segment (~$12B global menopause-therapy market, projected $24B by 2030 per Grand View Research), senolytics + SASP-modulators (D+Q [dasatinib + quercetin], fisetin, UBX0101, navitoclax/ABT-263) are the leading senolytic modalities being repositioned for ovarian aging (the OvaScience, Oviva, Celmatix, and lately Oviva Therapeutics pipelines), and a clean single-cell atlas of estropausal ovarian senescence is exactly the foundational data layer BB multiomics would deliver as a women's-health-longevity brief. ### 8. Four-axis score — peptide 0/5; AI-agent infrastructure 4/5 (single-cell atlas is the canonical input for AI-DD target nomination but lacks a companion arm); longevity 5/5 (estropausal senescence is core longevity biology with high commercial translation potential); cost 4/5 (mouse-model study with standard scRNA-seq is fast to ingest, raw files enable immediate re-analysis, modest cohort n=18 with single-modality design). The signal is actionable from the BB multiomics + longevity service stack as a women's-health-longevity senolytic target nomination brief. ### 9. Why it matters for BB + action — Ingest GSE267729 raw counts, run standard scRNA-seq pipeline (CellRanger → Seurat/Scanpy QC, integration, clustering, cell-type annotation via canonical markers DDX4/oocyte, AMH/granulosa, HSD3B/theca, WT1/stroma, CD45/immune), compute senescence scores per cell (SenNet, SenMayo, CellAge gene-sets), identify the senescence-prone cell-states (granulosa vs theca vs stromal vs immune), stratify SASP-secreting populations, and cross-reference with published ovarian-aging atlases (Tabula Muris Senis ovary, the Single-Cell Atlas of Ageing in Mice ovary subset). Package as a candidate list of senolytic + SASP-modulator targets for ovarian-aging therapy and integrate with the BB longevity senolytic shortlist (D+Q, fisetin, UBX1325, navitoclax). The first deliverable should be a women's-health-longevity senolytic target nomination brief, not a clinical recommendation. The mouse-model data should be flagged for cross-validation in human ovarian tissue atlases (e.g., the He et al. 2020 human ovarian-cell atlas subset) before client delivery. ### 10. Tracker note — Biotech Infrastructure / GEO-source scan continues as the primary feed (HF intel layer stable): The 2026-09-02 research-watcher scan returned 106 hits across 27 queries from the GEO-source scan only (collected_at 2026-09-01T21:01Z, mtime 2026-09-02 06:03 KST, source_errors empty, GEO-query-fan-out completed cleanly), making this the 3rd consecutive clean scan after the §20 silent-failure fix on 2026-08-29 (per the cron-silent-failure-diagnostics skill §20 — `bash run.sh scan` correctly invoked, log file `logs/2026-09-02-scan.log` is the expected size with full Python output, source_errors block empty, hits.jsonl written, scan.json written — §20 fix is stable for 3 consecutive days). The HF intel layer's `output/latest/intel.jsonl` carries 36 vendor-intel entries from prior runs (mtime 2026-09-02 00:00 KST — the standard pre-run intel refresh). The 3 NOVEL signals today come from the GEO-source scan only. The 13 NOVEL accessions surfaced today (score ≥4, mammalian, pdat ≥2026/06/01, absent from id:71-id:86) span 5 BB lanes: (a) **AI-DD + Clinical Oncology + Cancer Metabolism** — GSE330687 PD-L1/NSCLC/metabolism (selected as Signal 1), (b) **AI-DD + Refractory HCC + Epigenetic + Ferroptosis** — GSE237951 + GSE268195 EZH2/HCC/cysteine-metabolism/ferroptosis companion atlas (selected as Signal 2), (c) **Longevity + Reproductive Senescence** — GSE267729 estropausal/ovarian-aging scRNA (selected as Signal 3), (d) **Spatial Biology + Companion Atlas + Neuroscience Methodology** — GSE342289 + GSE342709 + GSE342738 Multiscale spatial transcriptomics of human amygdala [Xenium + Visium + Visium HD] (score 6/6/6, n=4/51/5, Homo sapiens, pdat 2026/08/24 = 9 days ago — the FRESHEST cross-platform spatial-biology companion atlas in the entire 2026-09-02 hits.jsonl and a direct multiomics-methodology demonstration input for the BB bioinformatics lane; reserve for tomorrow if the spatial-biology lane needs reinforcement), (e) **Cancer Immunotherapy + Tumor Biology** — GSE327213 Increased mRNA translation delays tumor initiation and exposes a therapeutic vulnerability in lung cancer (score 4, n=16, Mus musculus, pdat 2026/07/22 = 42 days ago; reserve for tomorrow if the cancer-immunotherapy lane needs reinforcement). The 13 NOVEL accessions also include several high-quality but lower-BB-fit candidates archived for future consideration: GSE317471 progeric-vascular-wall scRNA (longevity + aging + vascular, score 4, n=30, Mus musculus, pdat 2026/06/30), GSE298848 parkinsonian-striatum molecular atlas (neurodegeneration + Parkinson's + aging, score 4, n=19, Mus musculus, pdat 2026/06/01), GSE328460 single-cell resolution spatial transcriptomics of mucinous tubular and spindle cell carcinoma using CosMX (rare-cancer + spatial-biology + CosMX-platform, score 6, n=1, Homo sapiens, pdat 2026/07/20), GSE282124 single-cell spatial transcriptomics of FFPE biopsies reveals colitis-associated cell networks using Merscope (IBD + spatial-biology + Merscope-platform, score 6, n=1, Homo sapiens, pdat 2026/05/21), GSE306111 spatial transcriptomics of human FALD and normal livers (lung-fibrosis + FALD + spatial-biology, score 6, n=5, Homo sapiens, pdat 2026/03/01), GSE294765 skeletal-muscle-atlas-neuromuscular-junction (longevity + skeletal-muscle-aging, score 4, n=35, Mus musculus, pdat 2026/04/23), GSE316316 GDF15/GFRAL-sarcopenia-risk-association (longevity + GDF15 + sarcopenia, score 4, n=5, Mus musculus, pdat 2026/03/11), GSE337623 GDF15-suppresses-liver-inflammation-neuroendocrine-axis (longevity + GDF15 + liver-inflammation, score 4, n=4, Mus musculus, pdat 2026/08/10), GSE317623 AADAT-driven-Malate-CoQ10-immune-evasion-TNBC (cancer-immunotherapy + metabolism + TNBC, score 4, n=9, Mus musculus, pdat 2026/03/13), GSE332889 quinolinic-acid-metabolism-AKI-CKD-transition (metabolism + kidney-disease, score 4, n=10, Mus musculus, pdat 2026/05/23), GSE328655 sex-stratified-fasting-mouse-liver-atlas (metabolism + liver + atlas, score 4, n=80, Mus musculus, pdat 2026/04/28), GSE240503 insect-venom-allergen-immunotherapy-multiomics (immunotherapy + multiomics, score 6, n=187, Homo sapiens, pdat 2024/10/30), GSE230495 Factor-VIII-antisense-oligonucleotide-rescue (gene-therapy + antisense + hemophilia, score 6, n=32, Homo sapiens, pdat 2024/01/17), GSE263559 iPSC-3D-organoid-metabolic-liver-disease (longevity + regenerative-medicine + iPSC + liver, score 6, n=7, Homo sapiens, pdat 2026/04/01), GSE314598 FAP-directed-BiTE-atherosclerosis (vascular-immunotherapy + FAP-targeting + atherosclerosis, score 4, n=6, Mus musculus, pdat 2026/02/02), GSE291070 prostate-transcriptome-postmortem-interval-atlas (urology + atlas + postmortem-methodology, score 6, n=5, Homo sapiens, pdat 2026/01/14), GSE315651 PFOS-granulosa-cell-toxicokinetic-model (toxicology + reproduction + PFAS, score 6, n=32, Homo sapiens, pdat 2026/04/27). The recommended next moves are: (1) tomorrow's 06:00 KST scan should prioritize spatial-biology + neuroscience-methodology lane if the amygdala companion atlas is featured (GSE342289 + GSE342709 + GSE342738 = 60-sample cross-platform spatial-biology companion), (2) the EZH2/ferroptosis HCC companion atlas (GSE237951 + GSE268195, pdat 2024/10/25) should be cross-validated against newer 2025-2026 HCC ferroptosis atlases before client delivery — search terms 'EZH2 ferroptosis hepatocellular carcinoma' should surface 5-10 follow-up papers in PubMed for validation, (3) the PD-L1/NSCLC/metabolism atlas (GSE330687, pdat 2026/05/17) is recent enough to be ingestion-ready without further validation, (4) the ovarian-aging scRNA atlas (GSE267729) is fresh and ingestion-ready, and (5) the HF intel layer should be re-engaged in next week's scan to refresh the vendor-intel slot (Biomni-R0-32B-Preview, Boltz-2, Phylo, Anthropic-Science — all unchanged since 2026-08-28). --- ## 💼 Next Steps - **[Open GSE330687 in GEO (PD-L1 / NSCLC / metabolic-reprogramming / mitochondrial-remodeling)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE330687)** - **[Open GSE237951 in GEO (EZH2 / HCC / cysteine-metabolism / ferroptosis / RNA-seq, n=8)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE237951)** - **[Open GSE268195 in GEO (EZH2 / HCC / cysteine-metabolism / ferroptosis / CUT&Tag, n=12)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE268195)** - **[Open GSE267729 in GEO (ovarian-aging / estropausal / senescent-cell single-cell atlas, n=18)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE267729)** - **[Request PD-L1-metabolism + EZH2-ferroptosis-HCC + ovarian-aging-senescence brief](https://brownbio.tech/services/ai-drug-discovery#brief)** - **[View multiomics service](https://brownbio.tech/services/multiomics)** - **[View biostatx service](https://brownbio.tech/services/biostatx)** --- ## 📡 Provenance - **Source:** research-watcher (PubMed/GEO scan, 27 query families × Brown Biotech pipelines) - **Pipeline:** [`brown-biotech-daily-tech-digest`](https://github.com/ohbryt/brown-biotech-platform) — 06:00 KST cron - **Generated:** 2026-09-02 06:13 KST - **Repo:** `ohbryt/brown-biotech-platform` --- _Auto-published by `brown_biotech_research_digest_publisher.py` · [brownbio.tech](https://brownbio.tech) · Decision-ready research, daily._
Brown Biotech Research Digest — 2026-09-02
PubMed/GEO scan · research-watcher · 06:00 KST